Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Cohn

Showing results (561-570 of 612) with videos related to

Pageof 62
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2014
Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic CancerMitesh J Borad, Shantan G Reddy, Nathan Bahary, et al.
Pediatric Blood & Cancer|April 20, 2016
A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk NeuroblastomaJudith G Villablanca, Samuel L Volchenboum, Hwangeui Cho, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 21, 2013
A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancerA L Cohn, J Tabernero, J Maurel, et al.
Journal of Medicinal Chemistry|October 1, 2004
Structure-based discovery of nonpeptidic small organic compounds to block the T cell response to myelin basic proteinNiklas K U Koehler, Chao-Yie Yang, Judith Varady, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 12, 2017
Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III studyJ Tabernero, R R Hozak, T Yoshino, et al.
Cancer Research|July 21, 2012
Truncated DNMT3B isoform DNMT3B7 suppresses growth, induces differentiation, and alters DNA methylation in human neuroblastomaKelly R Ostler, Qiwei Yang, Timothy J Looney, et al.
Cell Reports|May 1, 2024
Small-molecule inhibition of the METTL3/METTL14 complex suppresses neuroblastoma tumor growth and promotes differentiationMonica Pomaville, Mohansrinivas Chennakesavalu, Pingluan Wang, et al.
Cancer|June 6, 2022
Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual diseaseAmi V Desai, Mark A Applebaum, Theodore G Karrison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2011
Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology GroupJudith G Villablanca, Wendy B London, Arlene Naranjo, et al.
British Journal of Cancer|September 15, 2012
Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG projectG Schleiermacher, V Mosseri, W B London, et al.
Pageof 62

Showing results (561-570 of 612) with videos related to

Sort By:
Pageof 62
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2014
Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic CancerMitesh J Borad, Shantan G Reddy, Nathan Bahary, et al.
Pediatric Blood & Cancer|April 20, 2016
A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk NeuroblastomaJudith G Villablanca, Samuel L Volchenboum, Hwangeui Cho, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 21, 2013
A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancerA L Cohn, J Tabernero, J Maurel, et al.
Journal of Medicinal Chemistry|October 1, 2004
Structure-based discovery of nonpeptidic small organic compounds to block the T cell response to myelin basic proteinNiklas K U Koehler, Chao-Yie Yang, Judith Varady, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 12, 2017
Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III studyJ Tabernero, R R Hozak, T Yoshino, et al.
Cancer Research|July 21, 2012
Truncated DNMT3B isoform DNMT3B7 suppresses growth, induces differentiation, and alters DNA methylation in human neuroblastomaKelly R Ostler, Qiwei Yang, Timothy J Looney, et al.
Cell Reports|May 1, 2024
Small-molecule inhibition of the METTL3/METTL14 complex suppresses neuroblastoma tumor growth and promotes differentiationMonica Pomaville, Mohansrinivas Chennakesavalu, Pingluan Wang, et al.
Cancer|June 6, 2022
Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual diseaseAmi V Desai, Mark A Applebaum, Theodore G Karrison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2011
Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology GroupJudith G Villablanca, Wendy B London, Arlene Naranjo, et al.
British Journal of Cancer|September 15, 2012
Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG projectG Schleiermacher, V Mosseri, W B London, et al.
Pageof 62